TY  - GEN
AU  - Rizvi,Naiyer A
AU  - Hellmann,Matthew D
AU  - Brahmer,Julie R
AU  - Juergens,Rosalyn A
AU  - Borghaei,Hossein
AU  - Gettinger,Scott
AU  - Chow,Laura Q
AU  - Gerber,David E
AU  - Laurie,Scott A
AU  - Goldman,Jonathan W
AU  - Shepherd,Frances A
AU  - Chen,Allen C
AU  - Shen,Yun
AU  - Nathan,Faith E
AU  - Harbison,Christopher T
AU  - Antonia,Scott
TI  - Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer
SN  - 1527-7755
PY  - 2017///0721
KW  - Aged
KW  - Antibodies, Monoclonal
KW  - administration & dosage
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - adverse effects
KW  - B7-H1 Antigen
KW  - biosynthesis
KW  - Carboplatin
KW  - Carcinoma, Non-Small-Cell Lung
KW  - drug therapy
KW  - Cisplatin
KW  - Cohort Studies
KW  - Deoxycytidine
KW  - Disease-Free Survival
KW  - Dose-Response Relationship, Drug
KW  - ErbB Receptors
KW  - genetics
KW  - Female
KW  - Humans
KW  - Lung Neoplasms
KW  - Male
KW  - Middle Aged
KW  - Nivolumab
KW  - Pemetrexed
KW  - Proto-Oncogene Proteins p21(ras)
KW  - Survival Rate
KW  - Gemcitabine
N1  - Publication Type: Clinical Trial, Phase I; Journal Article
UR  - https://doi.org/10.1200/JCO.2016.66.9861
ER  -